English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The objective of this retrospective study was to determine the role of 18 F-FDG PET/CT in a large cohort of 495 patients with metastatic neuroendocrine neoplasms (NENs) who were treated with peptide receptor radionuclide therapy (PRRT) with a long-term follow-up. Methods: The 495 patients were treated with 177 Lu- or 90 Y-DOTATOC/DOTATATE PRRT between February 2002 and July 2018. All subjects received both 68 Ga-DOTATOC/TATE/NOC and 18 F-FDG PET/CT before treatment and were followed 3-189 mo. Kaplan-Meier analysis, log-rank testing (Mantel-Cox), and Cox regression analysis were performed for overall survival (OS) and progression-free survival (PFS). Results: One hundred ninety-nine patients (40.2%) presented with pancreatic NENs, 49 with cancer of unknown primary, and 139 with midgut NENs, whereas the primary tumor was present in the rectum in 20, in the lung in 38, in the stomach in 8, and in other locations in 42. 18 F-FDG PET/CT was positive in 382 (77.2%) patients and negative in 113 (22.8%) before PRRT, whereas 100% were 68 Ga-DOTATOC/TATE/NOC-positive. For all patients, the median PFS and OS, defined from the start of PRRT, were 19.6 mo and 58.7 mo, respectively. Positive 18 F-FDG results predicted shorter PFS (18.5 mo vs. 24.1 mo; P = 0.0015) and OS (53.2 mo vs. 83.1 mo; P &lt; 0.001) than negative 18 F-FDG results. Among the cases of pancreatic NENs, the median OS was 52.8 mo in 18 F-FDG-positive subjects and 114.3 mo in 18 F-FDG-negative subjects ( P = 0.0006). For all patients positive for 18 F-FDG uptake, and a ratio of more than 2 for the highest SUV max on 68 Ga-somatostatin receptor (SSTR) PET to the most 18 F-FDG-avid tumor lesions, the median OS was 53.0 mo, compared with 43.4 mo in those patients with a ratio of less than 2 ( P = 0.030). For patients with no 18 F-FDG uptake (complete mismatch imaging pattern), the median OS was 108.3 mo versus 76.9 mo for an SUV max of more than 15.0 and an SUV max of 15.0 or less on 68 Ga-SSTR PET/CT, respectively. Conclusion: The presence of positive lesions on 18 F-FDG PET is an independent prognostic factor in patients with NENs treated with PRRT. Metabolic imaging with 18 F-FDG PET/CT complements the molecular imaging aspect of 68 Ga-SSTR PET/CT for the prognosis of survival after PRRT. High SSTR expression combined with negative 18 F-FDG PET/CT results is associated with the most favorable long-term prognosis.

the journal of nuclear medicine

Prognostic Value of <sup>18</sup>F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy

Prognostic Value of 18F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy

Prognostic Value of ¹⁸F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy